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Abstract
The side effects of amiodarone can be severe and potentially lethal (Vassallo &
Trohman, 2007). Amiodarone is frequently prescribed for supraventricular arrhythmias,
specifically atrial fibrillation, without any standardized monitoring for adverse effects. In
this quality improvement (QI) project, providers were encouraged to use a protocol
containing evidence-based recommendations built into the Electronic Health Record
(EHR ) when prescribing amiodarone in outpatient encounters. Providers were emailed
with education on the protocol and how to use it. A survey was sent to providers seven
weeks later to assess the usefulness and ease of use of the protocol. EHR reports
were run to assess how often the protocol was used pre- and post-email and how many
amiodarone orders were placed within the study timeline.
Results show providers only marginally thought the protocol was useful and easy to
use. Providers perceived that they did not prescribe amiodarone often enough to use
the protocol. However, EHR reports showed that the protocol was used only 2% of the
time amiodarone was prescribed. Survey scores were positive; however, qualitative
feedback indicated that providers perceived they did not have the opportunity to use the
protocol. Despite evidence-based education, most providers did not use the protocol.

Introduction
Problem Formation
Although amiodarone is only approved by the Federal Drug Administration (FDA)
to treat ventricular arrhythmias, many cardiologists, electrophysiologists, and advanced
practice providers specializing in cardiology and electrophysiology use amiodarone
therapy to treat persistent supraventricular arrhythmias, specifically atrial fibrillation
(afib); (Vassallo & Trohman, 2007). Amiodarone is considered a class III antiarrhythmic
potassium-channel blocker (Florek & Girzadas, 2020). Unlike other class III
antiarrhythmics, amiodarone also has beta-adrenergic receptor blocking, calciumchannel blocking, and sodium-channel blocking effects (Florek & Girzadas, 2020). Since
amiodarone has multiple unique pharmacological mechanisms, standardized monitoring
tests should guide providers in safely prescribing amiodarone.
Background
As the most common arrhythmia disorder, afib affects 1% of the world’s
population and 9% of people 75 years and older (Nesheiwat et al., 2020). It also occurs
more frequently in men than women and Caucasians than other races. Two million
Americans have a current afib diagnosis, and experts predict the incidence of afib will
double or triple by 2050 (Nesheiwat et al., 2020).
Problem Statement
Will providers report that a protocol for therapeutic drug monitoring of
amiodarone that is automated in the EHR is useful and easy to use? Will providing
education on evidence-based practice recommendations for the early detection of
common and severe side effects increase protocol use?

Needs Assessment
Amiodarone is frequently prescribed for supraventricular arrhythmias, specifically
afib, without any standardized monitoring for adverse effects. The goal is for all patients
to receive timely, evidence-based monitoring. Providers (physicians and advanced
practice providers) do not have a standardized, evidence-based protocol when
prescribing amiodarone. Providers are not up to date on current guidelines based on
varying requirements for monitoring. This variation from provider to provider
demonstrates a knowledge gap. Gaps in skill and practice include providers not
knowing how to use a protocol, not knowing how to refill medications electronically, and
not having a protocol. The method used to identify these gaps was direct observation
from clinic providers, including nurse practitioners (NP), Physician Assistants (PA), and
medical doctors (MD). Gaps in skill and practice were also identified by the practice
site's director of cardiology.
Significance
Consequences of afib arise from the atrioventricular (AV) asynchrony and the
rapid increase in rate and irregularity of the ventricular contractions. The rapid
ventricular response (RVR) can lead to left ventricular hypertrophy (LVH), causing
patients to be more symptomatic than those without RVR. This population benefits most
from the return to normal sinus rhythm (NSR); (Zimetbaum, 2007).
The side effects of amiodarone can be severe and potentially lethal (Vassallo &
Trohman, 2007). Adverse effects manifest in 15% of patients within the first year of
amiodarone use and up to 50% with long-term use (Florek & Girzadas, 2020).
Pulmonary toxicity, thyroid disorders, prolonged QT on electrocardiogram (ECG), skin

discoloration, corneal deposits, liver toxicity, and many drug-drug interactions are the
most common side effects (Florek & Girzadas, 2020). Close monitoring of side effects
with long-term therapy is needed to avoid harm with the long half-life.
Amiodarone is more effective in maintaining NSR than any other antiarrhythmic
medication (Zimetbaum, 2007). However, due to its highly lipophilic component and a
large volume of distribution, there is a delay in the onset of action and a long elimination
half-life (Zimetbaum, 2007). This delay in the onset of action is why side effects from
amiodarone can take months to appear. As amiodarone continues to outperform other
antiarrhythmics in sustaining NSR, clinicians would benefit from a useful and easy-touse protocol to monitor for signs and symptoms of side effects.
Protocols are often built into the electronic health record (EHR) through
SmartSets. In the EHR, a provider can order a group of orders that all relate to one
outcome. In a SmartSet, groups of orders are bundled together, making it convenient
for the provider to order multiple related orders simultaneously.
The benefits and the side effects of amiodarone are well documented in current
literature. What is significantly lacking is evidence that automated protocols built into the
EHR decrease unwanted side effects. It is also not well documented if providers believe
protocols to be useful and easy to use. This QI project will contribute to the literature to
show if having an evidence-based automated protocol will not only increase use but
also if providers find protocols helpful in providing evidence-based care.
As the nursing profession strives to implement evidence-based care, literature
that reflects the usefulness and ease of use of automated protocols will decrease the
provider burden of ensuring the most up-to-date guidelines are being used. We have

seen this implemented in primary care for the primary prevention of common diseases
with vaccine reminders and secondary prevention measures with diabetes screening,
colonoscopies, and mammograms (Bangash et al., 2020). This project aimed to
contribute to the nursing profession by taking a model already implemented in primary
care for primary and secondary prevention and using that model for therapeutic drug
monitoring patients on amiodarone.
Purpose Statement
This QI project aimed to determine if an amiodarone monitoring protocol would
be perceived as useful and easy to use. The protocol utilized the most up-to-date
research to make ordering therapeutic drug monitoring easier. It also aimed to see if
education on the evidence-based protocol would increase its use in the EHR.
Usefulness and ease of use were measured with a survey after asking prescribing
providers to use the protocol when prescribing amiodarone for seven weeks.
Objectives
MDs/PAs/NPs were encouraged to use the protocol for prescribing and refiling
amiodarone. Current research findings determined which tests are needed and how
frequently they need to be completed by patients on amiodarone therapy. It also
discerned which tests are not evidence-based in detecting adverse effects.
At the project’s practice site, there is an amiodarone refill SmartSet available in
outpatient encounters already available for use. Through an informal survey of
providers, most did not realize the SmartSet was available. After running an EHR report,
the data showed that this SmartSet had never been used by any provider at the practice
site. This SmartSet included more recommendations than what the literature supports.

Education was provided on the most up-to-date recommendations for monitoring and
accessing the protocol in the EHR.
Email list-serves of cardiology and electrophysiology providers were used to
distribute education on evidence-based recommended monitoring tests. The email
contained informed consent and a hyperlink to the survey administered through Google
forms. A password-protected laptop stored the data.
Theoretical Framework
An active implementation framework was used for this QI project. “The Active
Implementation Frameworks (AIFs) are an evidence-based set of frameworks to use
when attempting to put into practice any innovation of known dimensions” (Blanchard et
al., 2017). The AIFs are an evidence-based set of frameworks developed following a
systematic review and synthesis of the implementation evaluation literature (Blanchard
et al., 2017).
There are five themes present in AIFs, the first being Usable Innovations. The
researcher needs to ensure that education on the innovation or program can be taught
effectively enough to be used properly. The program needs clear descriptions. “An
innovation needs to be teachable, learnable, doable, and readily assessed in practice if
it is to be used effectively to reach all students” (AIRN, 2022).
The second theme seen in AIFs is an implementation team. The implementation
team assists in the full, effective, and sustained use of the program or innovation.
Teams define and utilize infrastructure to improve outcomes. The third theme is
implementation drivers. The drivers engage leadership and assure organizational
support, (NIRN, 2014).

The fourth theme seen in AIFs is the implementation stages. This is an outlined
non-linear timeline for project implementation. The four common stages in the
implementation process are exploration, installation, initial implementation, and full
implementation. The fifth theme is the improvement cycle, where all the people and
support structures from the previous themes come together to Plan, Do, Study, Act
(PDSA) (NIRN, 2014). This last theme is a cycle to ensure continued improvement in an
effective and useful manner.
To assess if this QI project is useful, clear descriptions and program components
needed to be identified. Operational definitions also needed to be clearly stated, and the
fidelity and usefulness needed to be objectively measured with an evidence-based tool.
Prior to the QI project, there was no program or practice process for using the
SmartSets with therapeutic drug monitoring for patients on amiodarone at the project
site. There was a SmartSet used in other settings within the healthcare organization.
This QI project lead conducted a systematic review of the literature on the
adverse effects of amiodarone use and their occurrence rates to determine usable
innovations. Organizational leadership was evaluated to see if the need for an
evidence-based protocol for therapeutic drug monitoring of patients on amiodarone is
needed or wanted. After the needs assessment, evidence-based recommendations
were implemented through the EHR. The improvement cycle was considered critical in
updating and changing the methods as feedback from the organizational stakeholders is
integral for continual improvement.

Literature Review
In a review of six high-quality, level I studies (Ad et al., 2016; Diederichsen et al.,
2016; Gillinov et al., 2016; Jennings & Baker, 2016; Ruzieh et al., 2019; Vamos &
Hohnloser, 2016), one high-quality level III (Harmon, 2020), and two high-quality Level
V (Pokorney et al., 2020; Vorperian et al., 1997), the evidence shows that monitoring for
side effects in amiodarone patients is essential. One Level V good quality case study
(Kapelios, 2018) showed how systemic the side effects of amiodarone are and how the
side effects can mimic other illnesses.
Ad et al., 2016 showed that the most critical concern in treating patients with
amiodarone is the associated side effects. However, treatment for a brief period (three
months) with close monitoring is safe and effective. Vorperian et al. (1997) found a
higher likelihood of experiencing several amiodarone-related adverse effects with
exposure to low daily doses of amiodarone. Although low-dose amiodarone may be well
tolerated, it is not free of adverse effects. The likelihood of experiencing adverse events
related to amiodarone was higher than that of placebo. The overall rate of adverse
events was low, and severe adverse events were rare (Ruzieh et al., 2019). Gillinov et
al., (2016) focused on the clinical effectiveness of amiodarone. Strategies for rate
control and rhythm control to treat postoperative atrial fibrillation were associated with
equal numbers of days of hospitalization, similar complication rates, and similarly low
rates of persistent atrial fibrillation 60 days after onset. Neither treatment strategy
showed a net clinical advantage (Gillinov et al., 2016). Jennings & Baker, 2016
suggests that preoperative amiodarone exposure does not increase mortality in cardiac
transplant recipients, questioning the usefulness of amiodarone. Diederichsen et al.,

(2016) looked explicitly at thyroid function. They found that amiodarone had a significant
impact on thyroid function after only one month, but with a fast recovery of thyroid
function after amiodarone discontinuation.
Literature Synthesis
The only conclusion common to each study is that monitoring side effects would
be beneficial. There are no guidelines or gold standards for practitioners to follow. A
significant amount of high-quality literature on the effects of amiodarone on each body
system exists. Still, a comprehensive study on the totality of amiodarone's side effects is
missing from current literature. Protocols and guidelines will help providers prescribe
amiodarone more safely. It is recommended that a protocol be developed for providers
to follow for the safe, effective, and evidence-based use of amiodarone to treat atrial
arrhythmias.
Project Implementation
Project Design
The project site is a Twin Cities cardiology and electrophysiology clinic. The
target population was 20 MDs and 16 advanced practice providers. The project would
be determined to be a success if at least 30% of providers report the protocol as useful,
easy to use, and likely to accept as determined by Davis's scale. The project would also
be determined successful if the protocol was used at least 50% of the time amiodarone
is ordered. The intervention was education provided via email covering the current
evidence-based practice of therapeutic drug monitoring while on amiodarone, education
on how to access the protocol in the EHR, and the usefulness of using the protocol
when practicing evidence-based care. EHR reports on the protocol use were generated

pre- and post-implementation. The frequency of prescribing amiodarone were also
compared against the frequency of protocol use. That data was gathered in an EHR
report.
Methods
Perceived usefulness correlates strongly with user acceptance. Fred D. Davis's
Perceived Usefulness, Perceived Ease of Use, and User Acceptance of Information
Technology survey was adapted to measure predictive user acceptance. This tool is a
valid measurement of usefulness with a reliability of .98 and ease with a reliability of .94
(Davis, 1989). Fred D. Davis permitted using the survey for this QI project via email.
Davis's survey has six statements on the perceived usefulness of information
technology and six on ease of use to determine if the information technology will be
adapted for future use. Two questions on his original survey do not pertain to the project
and were omitted. Each of the remaining ten questions asked the participant to rate how
they feel about each statement. The responses to choose from included: extremely
likely, quite likely, slightly likely, neither, slightly unlikely, quite unlikely, and extremely
unlikely. Each response was assigned a point: extremely likely=1, quite likely=2, slightly
likely=3, neither=4, slightly unlikely=5, quite unlikely=6, extremely unlikely=7. Once
averages were calculated, the protocol would be considered successful if the average
score was less than four for both categories.
The project also measured if educating on evidence-based practice and protocol
availability increases the use of the protocol. Protocol use pre- and post-implementation
was compared. The frequency of amiodarone prescription use was also compared to

that of amiodarone protocol use. If the protocol was used 50% of the time, amiodarone
is prescribed, the intervention would be considered successful.
The project site already had an amiodarone protocol built into the EHR. This
protocol had many recommended monitoring tests that were no longer evidence-based.
The last time this protocol was up to date was August 2004. Before any
implementations for this QI project, an EHR report was run to see how often the
amiodarone protocol had been used at the practice site. The report showed that no
provider at the project site had ever used the amiodarone protocol.
Project implementation:
On March 15th, 2022, the 36 providers received an email explaining the purpose
of this QI project. The communication provided education on evidence-based practice
for therapeutic drug monitoring of patients on amiodarone and explained how to access
the protocol in the EHR. It explained how the protocol could be used to deliver
evidence-based care. The email also gave informed consent and explained that a
follow-up email would contain a link to a survey asking the providers for their feedback
on using the protocol. On April 12th, 2022, a reminder email with the same information
was sent to the same 36 providers.
Seven weeks after the initial email, on May 4th, 2022, another email was sent
explaining the project's purpose and containing a link to a survey. The survey was
administered through a Google Form, and all responses were anonymous. With this
survey was a reminder that the providers were still able to use the protocol. Nine weeks
after the initial email, EHR reports were run to assess how often the amiodarone
protocol was used. A second EHR report was run to determine how many amiodarone

prescriptions were written since the original implementation email. This second report
allowed for a comparison between how often the protocol was used versus how often
amiodarone was prescribed.
Social Justice Considerations
Race is embedded into the decisions made by many healthcare providers,
especially in cardiology (Vyas et al., 2020). “By embedding race into the basic data and
decisions of health care, these algorithms propagate race-based medicine. Many of
these race-adjusted algorithms guide decisions in ways that may direct more attention
or resources to white patients than to members of racial and ethnic minorities” (Vyas et
al., 2020). The American Heart Association (AHA) Get with the Guidelines–Heart
Failure Risk Score (Peterson et al., 2010) and The Society of Thoracic Surgeons both
use race-based guidelines that steer resources away from non-Hispanic blacks without
giving any evidence as to why this is built into the risk-algorithm (Researchers at
Massachusetts General Hospital Target Cardiac Surgery, 2018).
Although race is not built into algorithms used in electrophysiology, racial
disparities persist. Rodriguez et al., (2019) found that minority patients with
cardiovascular implantable electronic device infections (CIEDIs) experienced more
procedural complications during extraction and had a significantly longer index
hospitalization length than Caucasian patients. "Our minority cohort of patients was on
average five years younger and had infections associated with typically less virulent
organisms than our Caucasian cohort, yet despite these findings, their total
hospitalization length of stay was approximately two days longer on average"
(Rodriguez et al., 2019). Sridhar et al., (2016) looked at the Nationwide Inpatient

Sample database to identify all patients with cardiac resynchronization therapy (CRT)
implantation from 2002 to 2010. They found that significant and persistent gender and
racial disparities favoring men (71.4%) and white (79.6%), respectively, were noted in
all years.
The American College of Cardiology/American Heart Association (ACC/AHA)
Task Force on Clinical Practice Guidelines state:
The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure
that the guideline writing committee includes requisite expertise and is
representative of the broader medical community by selecting experts from
a broad array of backgrounds, representing different geographic regions,
sexes, races, ethnicities, intellectual perspectives/biases, and scopes of
clinical practice. The ACC and AHA have rigorous policies and methods to
ensure that documents are developed without bias or improper influence.
(Arnett et al., 2019)
The studies mentioned above demonstrate that the standards set by ACC/AHA are not
always upheld. There are plenty of cardiac screening tools that propagate race-based
medicine. With the known disparities minorities face when receiving cardiac care, the
amiodarone monitoring protocol will help to equalize screening for all patients. Race will
not be factored into the protocol as there is no evidence that people of different
ethnicities need different monitoring.

Evaluation
Analysis
The purpose of this project was to determine if providers reported a protocol for
prescribing and refilling amiodarone was useful and easy to use and if providing
education on evidence-based practice increased the use of the protocols. The data
collected included frequency in protocol use pre-and post-education/email
implementation. The frequency of amiodarone orders was compared to determine how
often the protocol was being used versus how often amiodarone was being prescribed.
This was to assure that the protocol was not being used due to a lack of amiodarone
orders.
An EHR report run before the education showed that the previous amiodarone
protocol was never used at any of the outpatient clinics. From March 15th, 2022, the
date of the first email, to May 17th, 2022, the day the survey closed, amiodarone was
prescribed 209 times within the practice site’s cardiology and electrophysiology group.
A second EHR report was run after the survey ended and showed that between March
15th to May 17th, the amiodarone protocol was used five times. These EHR reports
reflect that even though there was an increase in the use of the amiodarone protocol
after implementation, the percentage of amiodarone orders where the protocol was
being used was very small, 2.39% of the time.
Nine providers responded to the Google form survey. Of those that responded,
seven were NP/PAs and two were MD/DOs. Seven of the respondents reported greater
than 10 years of practice and cardiology. One of the respondents reported having over
five years but less than 10 years, and another reported having between one and five

years of experience. Out of the nine responders, seven were female, and two were
male.
Participants were asked to give a score that reflected their level of agreement
using a scale of 1 to 7, with 1 for extremely agree and 7 for extremely disagree:
(1)Extremely agree (2)Quite agree (3) Slightly agree (4) Neither (5) Slightly disagree (6)
Quite disagree (7) Extremely disagree. At this practice site, protocols in the EHR are
called SmartSets. When asked if using the SmartSet enabled them to accomplish tasks
more quickly, the average response was 3.55.

When asked if the amiodarone SmartSet improved job performance the average
response was 3.55.

When asked if using the SmartSet increased their productivity, the average response
was 3.55.

When asked if using the SmartSet made their job easier to do, the average response
was 3.55.

When asked if the amiodarone SmartSet was useful, the average response was 3.67.

When asked if it was easy to get the SmartSet to do what they want, the average
response was 3.22.

When asked if interacting with the SmartSet was clear and understandable, the average
answer was 3.0.

When asked if interacting with the SmartSet was flexible, the average answer was
3.375.

When asked if it was easy to become skillful at using the SmartSet, the average
answer was 3.22.

When asked if the SmartSet was easy to use, the average answer was 3.0.

The second half of the survey included free text questions about the protocol.
The first question asked participants to state what they liked most about using the
protocol. Feedback in this section included responses stating they never used it, it was
easy to use, a good idea for streamlining amiodarone tapering, automated ordering
routine labs, and “it's quick.” The second free text question asks participants what they
liked least about the amiodarone protocol. Responses here included comments that
they did not use it, that there were too many automatic orders results (X-ray etc.) for
which they did not want the results, wanted to know more about the process of following
up with abnormal results, need to add it to the favorites list, opening it at another site,
and not routinely prescribing amiodarone.
Participants were then encouraged to make a statement on what they would like
to see changed about the protocol. Feedback here included fewer preset imaging labs
and allowing providers to select their preferences. Another participant stated they would
like to know what was learned from it, they needed to use it more and get more
comfortable using it. Another participant stated they would like to see an elimination of

the options that raise costs without benefits. The last question on the survey asked if
there were any other thoughts for the amiodarone protocol. Feedback here includes that
it is a good idea that needs some perfecting and that it would have been very helpful
had it been needed.
Interpretation of results.
The survey had a 25% participation rate given that nine out of the 36 providers
responded. On average, the providers that responded were in favor of the protocol,
given they deemed it to be useful and easy to use. However, from March 10th to May
17th, out of the 209 amiodarone orders prescribed, the protocol was only used five
times. The infrequency of the use of the amiodarone protocol could bring into question
the validity of the results. Even though providers were provided education on the benefit
of an automated protocol, information on the most recent evidence-based practice, and
screenshot images on how to access the protocol, a vast majority of providers, when
given the opportunity to use the protocol, did not use it.
Discussion
The survey results indicate that providers thought a useful and easy-to-use
protocol for monitoring outpatients on amiodarone would be an asset to their practice.
All the average scores were positive (left of the neutral point). The feedback given in the
free text questions reflected that many providers thought they did not have the
opportunity to use the protocol. The EHR report showed that between March 15 to 2022
and May 17th, 2022, amiodarone was prescribed in an outpatient encounter 209 times.
There appears to be a disconnect between perceived frequency and actual frequency of
amiodarone orders. In the free text section, providers believed there were too many

orders in the protocol and that providers did not necessarily want the results of those
tests. This could reflect the overburden of providers with test results in managing
patients outside of clinic visits. This may indicate a need for further education on the
importance of why therapeutic drug monitoring tests.
Limitation of Project
One major limitation to the project is that very few providers used the amiodarone
protocol when prescribing. The project aim was to determine whether providers think an
amiodarone protocol is useful and easy to use. Because so few providers used the
protocol, it is difficult to determine if the aim was met. It is difficult to generalize with
such a low rate of use. There was a 25% response to the survey. However, several of
the comments at the end of the survey stated that the responder never used the
protocol. The second major limitation to the project was that only 25% of possible
responders answered the questions in the survey. Data was to be considered valid if at
least 30% of providers responded. With a low turnout of responses, it is difficult to
determine whether the data collected can be generalized to the entire group. A third
limitation to the project is distinguishing if there is a difference between general
cardiology and electrophysiology providers. This question was not asked in the
demographic data of the survey.
Conclusion
Theoretically, people believe useful tools and easy-to-use shortcuts make their
jobs easier. This tool was introduced, but very few providers used it even though
amiodarone was often prescribed. One variable that could have potentially played a role
and could not be controlled for is that during the same period, there was a major EHR

update affecting how providers review results. Traditionally, providers do not favor EHR
updates, and they may have been too overburdened with learning the new update to
incorporate a new protocol into their practice.
It was also the time of year that this health organization completed its annual
employee engagement survey. Employees received frequent emails encouraging them
to complete the employee engagement survey during the same time as this study.
Perhaps the over-communication about the employee engagement survey led to this QI
survey being lost in the provider’s emails.
These conclusions call into question the usefulness of updating protocols with
the most recent evidence-based recommendations if these protocols are not being
used.
Recommendations
If the study were to be repeated, the implementation should occur when there are
no planned EHR updates. It would also be wise to ask for survey participation outside of
a planned annual survey. Perhaps another method of educating providers on the benefit
of using automated protocols built into the EHR would have been more effective than an
email. Another recommendation is to have an EHR super user teach a class on using
the protocol, and providers could have hands-on practice using the technology before
needing it in a clinical setting.
Providers are already overburdened with extra work outside of their direct patient
care hours, such as responding to telephone encounters and medical messages,
providing a plan of care after test results are in, and ensuring that all their
documentation is up to compliance standards. Any sort of QI project will only add to

their workload. Providers also often feel that EHR updates and EHR shortcuts are not
beneficial to their practice.
Especially during COVID, the importance of QI projects has faded into the
background of most health care organizations. Without any evidence that it saves
money and without anyone who can bridge between direct patient care and QI projects,
it is difficult to prioritize QI projects in healthcare organizations. One way to combat this
would be to identify a QI champion. This could be a Doctor of Nursing Practice (DNP) to
lead QI initiatives. Some healthcare organizations employ a QI champion who works
with providers to identify needs within the patient care departments and bridges the gap
between the administration and infrastructure systems. This is a challenging and often
impossible gap to close without someone uniquely identified to facilitate QI projects that
will be useful to those providing direct care. Not involving those providing the care would
be a missed opportunity to improve patient care.
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